Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00133822 · ClinicalTrials.gov registry record · Phase 1

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

A Phase 1 study of Post-Traumatic Stress Disorders, sponsored by Emory University.

Completed
Registry status
Phase 1
Development phase
65
Enrollment target
3
Study locations

NCT00133822: Completed Phase 1 study of Post-Traumatic Stress Disorders, sponsored by Emory University.

NCT00133822 is a Phase 1 study of Post-Traumatic Stress Disorders that has completed, run by Emory University. The registered enrollment target is 65 participants, below the 119-participant average among 9 other Post-Traumatic Stress Disorders trials with a reported enrollment target (45% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00133822, a Phase 1 study of Post-Traumatic Stress Disorders, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 1
Development phase
65 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine whether the administration of risperidone is effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant post-traumatic stress disorder (PTSD) in civilians.

Interventions

  • DRUG Sertraline and Risperidone

Study Locations (3)

Georgia

  • Emory University School of Medicine - Atlanta

North Carolina

  • Duke University Medical Center South - Durham

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2004-04
Est. Completion 2006-09
Phase Phase 1
Emory University

1,208 total trials

What the finished NCT00133822 record still lists

NCT00133822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 119-participant average among 9 other Post-Traumatic Stress Disorders trials with a reported enrollment target (45% lower).

The record links to 1 condition, with Post-Traumatic Stress Disorders appearing as the primary indexed condition, and to 1 intervention - of which Sertraline and Risperidone is the first listed.

NCT00133822 reports a single indexed study location in Georgia, North Carolina, South Carolina.

Frequently Asked Questions

What is clinical trial NCT00133822 about?

NCT00133822 is a clinical study titled "Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial". The purpose of this study is to determine whether the administration of risperidone is effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant post-traumatic stress disorder (PTSD) in civilians.

What is the current status of trial NCT00133822?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2004-04. Estimated completion is 2006-09.

What conditions does trial NCT00133822 study?

This clinical trial studies the following conditions: Post-Traumatic Stress Disorders.

What interventions are being tested in trial NCT00133822?

The interventions under investigation include: Sertraline and Risperidone (DRUG).

Who is sponsoring clinical trial NCT00133822?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00133822 being conducted?

This trial has 3 study locations across Georgia, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Traumatic Stress Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00133822's enrollment target sits among peer trials

65 7th of 9 higher than 3 of 9 other Post-Traumatic Stress Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post-Traumatic Stress Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00133822, the US trial registry maintained by the National Library of Medicine. NCT00133822 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.